Terns Pharmaceuticals Inc. has synthesized glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity and liver diseases.
Krystal Biotech Inc. has received IND clearance from the FDA for KB-408 for the treatment of α1-antitrypsin deficiency (AATD). KB-408 is a modified, replication-defective, nonintegrating HSV-1-derived vector carrying two full-length copies of the serpin family A member 1 gene (SERPINA1) to enable expression of α1-antitrypsin (AAT).
Aiming to provide additional utility and information to its continuous glucose monitors (CGMs), Dexcom Inc. is tying in the nutrition information provided by Rxfood Corp.’s app for customers in Canada. Clinics, hospitals, pharmacies, health plans, employers and others can make the app available to the beneficiaries and patients who use the Dexcom G6 or G7 systems, once the program is rolled out.
The contribution of the soluble form of urokinase-type plasminogen activator receptor (suPAR) as a risk factor for chronic kidney diseases (CKD) is well known. Researchers from Rush University Medical Center, Harvard Medical School and collaborators have now identified D2D3, a suPAR fragment, as responsible for causing double injury, both to the kidney and pancreas, thus resulting in glomerular disease and insulin-dependent diabetes.
Celros Biotech Co. Ltd. has identified hydantoin derivatives acting as cytochrome b-245 heavy chain (CYBB; NOX2) and NADPH oxidase 4 (NOX4) inhibitors with blood-brain barrier permeability and metabolic stability reported to be useful for the treatment of atherosclerosis, Alzheimer’s disease, cirrhosis, diabetes, cancer, glomerulonephritis, psoriasis and rheumatoid arthritis, among others.
Inversago Pharma Inc. has synthesized cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, diabetes, fibrosis, hypertension, irritable bowel syndrome, metabolic syndrome, alopecia and Prader-Willi syndrome.
Neurocrine Biosciences Inc.’s positive top-line data from the phase III study called Cahtalyst in classic congenital adrenal hyperplasia (CAH) further whetted Wall Street’s appetite for soon-to-come results in the same indication from Spruce Therapeutics Inc.
Precision Biosciences Inc. uses its proprietary Arcus platform to develop in vivo gene editing therapies and has outlined new data from its wholly owned and partnered pipeline.
RSS
